Search PubMed⌕ Search

Biomedical subjects

D W Cahill

Publications and source records attributed to D W Cahill.

At least 37 records · Page 2Linked to original sources
PubMed1996

Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation.

BACKGROUND: The immunosuppressant cyclosporine-A (CsA) is the primary drug for neural transplantation in Parkinson's disease. However, little is known of its direct effects on movement disorders. Our previous observation of increased locomotor activity in normal rats injected with CsA prompted us to investigate further the effects of CsA on hemiparkinsonian rats. METHODS: We examined the effects of CsA with 6-hydroxydopamine-induced hemiparkinsonism. The animals were randomly assigned to either intraperitoneal injections of CsA (15 mg/kg) or olive oil (the vehicle used for CsA) for 32 days. All animals were tested using the elevated body swing test, and the spontaneous and the amphetamine-induced rotational tests prior to and following the 32-day drug regimen. RESULTS: As revealed by the elevated body swing test, CsA-treated rats had significantly higher mean percent contralateral (to the lesion) swings compared to their pretreatment level (p < 0.01) or to vehicle-treated rats at posttreatment (p < 0.005). In the spontaneous rotational test, CsA-treated rats displayed ipsilateral (to the lesion) rotations which were significantly higher than their pretreatment rotational behavior (p < 0.005) or the posttreatment rotational behavior of olive oil-treated rats (p < 0.0001). Similarly, CsA-treated rats displayed significantly more amphetamine-induced ipsilateral rotations compared to their or the olive oil-treated rats pretreatment level (p < 0.05). CONCLUSION: Our present observations extend our previous findings on motor alterations produced by CsA on normal rats to hemiparkinsonian rats. These results taken together would suggest that CsA may interact with the locomotor effects observed following neural transplantation with adjunctive CsA immunosuppression.

Animals↗
PubMed1996

CNS immunological modulation of neural graft rejection and survival.

Neural transplantation therapy as a possible alternative treatment for neurological movement disorders, such as in Parkinson's disease (PD), has accentuated research interest on the immune status of the central nervous system (CNS). Most animal studies concerned with neural transplantation for the treatment of PD have utilized dopamine (DA) neurons from tissues of the embryonic ventral mesencephalon. Rat embryonic DA neurons, grafted either as solid blocks or dissociated into a cell suspension and stereotaxically injected intraparenchymally into a rat lesion model of PD, have been shown to survive and form connections with the host brain, and ameliorate the behavioral deficits of PD. Similarly, studies on nonhuman primate models of PD provide considerable support for neural transplantation of DA neurons as an experimental clinical procedure for the treatment of PD. To this end, experimental clinical trials have been centered upon transplantation of the embryonic ventral mesencephalic cells for PD patients. Although not conclusive, the findings from clinical studies have provided some evidence that most patients with marked increases in fluorodopa uptake (indicating graft survival) have been immunosuppressed. Furthermore, immune reactions have been observed in rats xenografted with human embryonic tissue. Of note, embryonic ventral mesencephalic tissues compared to adult tissues produce better morphological and long-lasting behavioral amelioration of the neurobehavioral deficits of PD, thus advocating the use of grafts from young donors (embryo) to circumvent the CNS immune rejection. The possible graft rejection due to CNS immune reactions, coupled with the social and ethical problems surrounding the use of embryonic neural tissue, and the logistical problems concerning tissue availability have prompted the development of alternative sources of DA-secreting cells. To circumvent these obstacles, several methods have been suggested including the use of immunosuppressants such as Cyclosporine-A, transplantation of autografts, polymer-encapsulated DA-secreting cells, co-culturing and co-transplantation of DA-secreting cells with microcarrier beads, with Sertoli cells, or with fragments of a monoclonal antibody that can mask the MHC class I antigens, and genetically modifying cells that can withstand CNS immune reactions. Some of these techniques allow transplantation of allograft (same species transplantation), or even xenograft (cross species transplantation) without immunosuppression of the recipient. We discuss recent CNS immunosuppression techniques that pose some promise for enhanced survival of neural grafts. When possible, advantages and disadvantages of each method are presented. Hopefully, such critical analysis of different immunosuppression techniques will produce innovated ideas that will lead to a better understanding of CNS immune response and its modulatory function on graft rejection and survival.

Adrenal Medulla↗
PubMed1996

Surgical management of malignant tumors of the adult bony spine.

Modern diagnostic imaging techniques and new methods for anterior and posterior decompression and reconstruction of the bony spinal column have dramatically improved the surgeon's ability to treat malignant tumors of the adult bony spine. The day of the laminectomy and Harrington rod reconstruction has passed, and an aggressive surgical approach is now justified for many primary and secondary malignant lesions of the spine. This article addresses the diagnosis and therapy of malignant tumors of the bony spine, emphasizing the common primary tumors of the spine and even more common metastatic lesions. Specific tumor types and therapeutic approaches at different levels of the spine are addressed, and newer techniques available to the treating clinician are reviewed. Current specific approaches to myeloma/plasmacytoma, breast carcinoma, prostate carcinoma, lung carcinoma, renal cell carcinoma, and chordoma and primary rectal carcinoma of the sacrum are reviewed in detail.

Adult↗
PubMed1996

Free radical damage and oxidative stress in Huntington's disease.

Bioenergetic defects and oxidative stress may be critical links in an excitotoxic mechanism of neuronal death. Oxidative stress, a condition describing the production of oxygen radicals beyond a threshold for proper antioxidant neutralization, has been implicated as a pathologic condition in several neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. In addition, oxygen radicals are known to be important mediators in acute pathologies, in the theory of senescence, cancer, as well as our healthy immune system. Although free radicals may have a special chemical nature which allows them to perform important cellular functions, they are a damaging entity whose reactivity may play a part in the development of cellular compromises that can kill a neuron. In this review, the free radicals in biological systems, the defense systems against them, and the damaging interactions, i.e., oxidative stress, which they confer are discussed. The descriptions provided raise the hypothesis that an imbalance between the production and removal of radicals would be abrasive on a neuron. Accordingly, the neurodegeneration initially caused by gene mutation in Huntington's disease may be further worsened by free radical damage underlied by oxidative stress. This article reviews existing data on the free radical damage and the oxidative stress, which are primarily directed towards Parkinson's disease and Alzheimer's disease, and whenever possible relates such mechanisms to Huntington's disease.

Alzheimer Disease↗
PubMed1995

Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.

Huntington's disease is a progressive neurodegenerative disorder associated with severe degeneration of basal ganglia neurons, especially the intrinsic neurons of the striatum, and characterized by involuntary abnormal choreiform movements and progressive dementia. With the discovery of the gene underlying HD, genetic therapy may be the next logical step towards finding a cure, but no such treatment is currently available. Animal models that closely mimic the neurobiological and clinical symptoms of the disease may offer an alternative approach for the development of new therapies. We report that systemic administration of 3-nitropropionic acid, an inhibitor of the mitochondrial citric acid cycle, results in a progressive locomotor deterioration resembling that of HD. We further demonstrate that manipulating the time course of 3-nitropropionic acid injections leads to sustained hyperactivity (early HD) or hypoactivity (advanced HD). These data suggest that this animal model can be used to test experimental treatments for HD across different stages of the disease.

Animals↗
PubMed1995

Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.

Severe degeneration of basal ganglia neurons, particularly the intrinsic neurons of the striatum, is the major underlying neuropathology implicated in clinical attributes of Huntington's disease (HD). The excitotoxin-lesioned striatum provides a useful model for evaluating behavioral parameters of HD. Animals with unilateral excitotoxic lesions exhibit asymmetrical rotational behavior in response to dopamine agonists, such as apomorphine. However, the observed behavior is a pharmacological reaction, and subject to sensitization effects. A behavioral test using undrugged animals may demonstrate a more natural response of the animals to the lesion effects. Recently, we have developed the 'drug-free' elevated body swing test (EBST), and demonstrated that hemiparkinsonian rats exhibited significant biased swing activity. In the present study, we observed that animals with unilateral intrastriatal 3-nitropropionic acid or quinolinic acid lesions displayed a significant biased swing activity with the direction ipsilateral to the lesioned side of the brain. This ipsilateral swing corresponded to the ipsilateral rotational behavior exhibited by the lesioned animals when challenged with apomorphine. The present results demonstrated that the EBST is a sensitive measure for characterizing asymmetrical behavior in animals with striatal lesions.

Animals↗
PubMed1995

(-)-nicotine protects against systemic kainic acid-induced excitotoxic effects.

(-)-Nicotine was shown to produce in vivo protection against neurobehavioral effects caused by systemically administered kainic acid (KA), an excitotoxin that has been widely used to induce temporal lobe convulsions including "wet dog shakes" in experimental animals. Rats pretreated with (-)-nicotine (0.5 mg/kg sc) 15 min before receiving KA (12.0 mg/kg sc) exhibited a marked reduction (P < 0.5) in the number of wet dog shakes when compared to saline-pretreated rats. Similarly, little visible brain damage was found in the (-)-nicotine-pretreated rats, but a widespread reduction in acetylcholinesterase-positive neurons was noted in the hippocampal areas of the saline-pretreated animals. While the mechanism of neuroprotection of (-)-nicotine is still not known, these findings suggest that (-)-nicotine may act as a therapeutic agent for putative excitotoxin-mediated disorders.

Animals↗
PubMed1995

Locomotor and passive avoidance deficits following occlusion of the middle cerebral artery.

The characterization of sensory, motor and cognitive dysfunctions following occlusion of the middle cerebral artery (MCA) is prerequisite to investigations of treatment intervention in animal models of ischemia. Different strategies are used to induce ischemia, but the focal, transient occlusion of the MCA has been reported to result in neuropathology most similar to that seen in clinical cerebral ischemia. If the MCA occlusion technique results in a stroke animal model, then the behavioral impairments inherent in stroke should be manifested in this model. The present study provides a further characterization of behavioral alterations associated with MCA occlusion. Sprague-Dawley rats underwent temporal occlusion of the right MCA, and at 1 mo and 2 mo postischemia, were subsequently tested in passive avoidance behavior, motor coordination, asymmetrical motor behavior, neurological functioning, nocturnal spontaneous and amphetamine-induced locomotor activity, and haloperidol-induced catalepsy. Results revealed that ischemic rats showed long-term impairments in sensory, motor and cognitive functions. The discrepancy with other studies reporting temporal MCA-induced behavioral deficits may be due to techniques used to induce ischemia and consequent CNS damage, differences in time period of testing (i.e., immediate vs. later postischemia, nighttime vs. daytime), number of test-retests over the course of the experiment, and age of the animals. The mechanism involved in the MCA-induced behavioral changes may be represented by loss of dopamine receptors on striatal neurons. Histological analysis revealed damage limited to the lateral aspect of the striatum. These behavioral and anatomical data support MCA occlusion as a model of ischemia, and elucidate important factors that should be controlled for in characterizing the MCA-induced neuropathological alterations.

Acetylcholinesterase↗
PubMed1995

Striatal dopamine-mediated motor behavior is altered following occlusion of the middle cerebral artery.

Cerebral infarct (stroke) causes striatal damage with subsequent deterioration of sensorimotor and cognitive functions that may be mediated by the dopamine receptor system. In the present study, transient, focal ischemia was induced in Sprague-Dawley rats by middle cerebral artery occlusion. Ischemic animals exhibited significantly less dopamine antagonist (haloperidol)-induced catalepsy and more dopamine agonist (amphetamine)-induced hyperactivity than sham-operated animals. Younger ischemic animals showed more profound behavioral alteration but also displayed greater recovery over time than older ischemic animals. Histologic data revealed a lateral striatal lesion in all ischemic animals. These results place the striatal dopaminergic system as a possible strategic venue for the treatment of cerebral ischemia. In addition, aging is found to be a risk factor for stroke as noted in humans.

Animals↗
PubMed1995

Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.

Previous animal studies have demonstrated that systemic administration of 3-nitropropionic acid (3-NP) leads to neuropathological changes similar to those seen in Huntington's disease (HD). Recently, we reported hypoactivity in 6- and 10-week old rats treated with systemic 3-NP (IP, 10 mg/kg/day) once every 4 days for 28 days. Although these behavioral results seem to differ from the observed hyperactivity in most excitotoxic models of HD, 3-NP may provide a better model of juvenile onset and advanced HD. In the present study, older rats were similarly treated with 3-NP to further characterize the reported age dependency of striatal neuronal death caused by 3-NP. Hypoactivity was observed in 14- and 28-week old rats with the latter demonstrating more profound features. The present study also provided the first direct evidence of a 3-NP effect on passive avoidance behavior. Experimental and control animals showed no significant difference in daytime acquisition and retention of a passive avoidance task. However, when the retention tests were conducted during the night time (in contrast to previous daytime tests), 3-NP-treated animals exhibited significant retention deficits. In addition, the neuropathological effects of 3-NP were determined by Nissl, AChE and NADPH-diaphorase histochemistry. Metabolic activity was studied using cytochrome oxidase activity as an index. Results revealed striatal glial infiltration, loss of intrinsic striatal cholinergic neurons, but some sparing of large AChE positive neurons, minimal damage of NADPH-diaphorase-containing neurons, and very slight, if any, alterations in cytochrome oxidase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1994

Intrastriatal 3-nitropropionic acid: a behavioral assessment.

Systemic injections of 3-nitropropionic acid (3-NP) in Sprague-Dawley rats have led to (1) hypoactivity that resembles juvenile onset and advanced Huntington's disease (HD), and (2) impairment in contextual retention of passive avoidance. Since it has been established that 3-NP exerts its primary effects in the striatum, we selected intrastriatal injections to more thoroughly understand the direct behavioral effects of 3-NP. Each 14-week old rat received bilateral intrastriatal injections of one of the following: 500 and 750 nmol of 3-NP or vehicle (0.9% saline). At seven days following surgery, the animals were tested for spontaneous locomotor behavior and passive avoidance behavior. Results revealed deficits in both locomotor activity and passive avoidance learning. The animals injected with 500 and 750 nmol of 3-NP were significantly hypoactive compared with control animals. Similarly, the 2 groups of animals were severely impaired in the retention of passive avoidance compared with control. The 3 groups, however, did not differ in their acquisition of this learning task. Macroscopic analyses of brains of these animals revealed that 500 and 750 nmol of 3-NP caused severe loss of neuronal cell bodies and marked glial infiltration in the medial aspect of the striatum. Larger lesions showed a necrotic cavity at the injection site. In comparison with systemic administration of 3-NP, intrastriatal injections resulted in more profound hypoactivity, greater loss of passive avoidance retention, and more severe striatal damage.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1994

Systemic 3-nitropropionic acid: long-term effects on locomotor behavior.

Systemic administration of 3-nitropropionic acid (3-NP) results in striatal atrophy by irreversibly inhibiting the citric acid cycle, and thereby resulting in cellular ATP depletion. The neuropathological outcome following 3-NP injections is thought to resemble that seen in Huntington's disease (HD) [1]. The current study administered systemic injections in 6- and 10-week-old rats of low-dose 3-NP every other 4 days for a period of 28 days in order to investigate the effects on locomotor behavior and striatal D1 dopamine receptor binding. Experimental and control animals received intraperitoneal injections of 3-NP (10 mg/kg in 0.9% saline) and 0.9% saline, respectively. Animals were tested behaviorally prior to the first and after the last 3-NP administration. Brains were then removed and striatal tissue samples were analyzed for D1 dopamine receptor binding using [3H]SCH23390. Behaviorally, 6-week-old injected animals developed bradykinesia with no signs of stiffness or rigidity, while 10-week-old injected animals displayed an uncoordinated gait, stiffness and ventral recumbency with hind limbs extended in a rigid or fixed position. These visual observations of hypoactivity were supported by a significant decline in both experimental groups' locomotor activity as measured by Digiscan monitors. Furthermore, [3H]SCH23390 specific binding to D1 dopamine receptors revealed a small but significant decrease in 10-week-old injected animals compared to controls. These results demonstrate that both 6- and 10-week-old rats do exhibit behavioral alterations after long-term 3-NP administration, however the former may not show accompanying gross D1 receptor changes.

Aging↗
PubMed1994

Avian telencephalon and body weight.

The neurological mechanisms associated with weight gain in animals have been extensively studied in mammals, but relatively little investigation has been carried out in birds. As in mammals, it has been shown that lesion of the ventromedial nucleus of the hypothalamus leads to hyperphagia and obesity in several species of birds. Likewise, bilateral lesions of the lateral hypothalamus result in aphagia and weight loss. Therefore, at the level of the hypothalamus, control of body weight appears to be controlled by similar neurological mechanisms in all homeothermic species via modulation of the sympathetic nervous system. Because of the role of the mammalian striatum in body weight regulation, body weight data from various manipulative studies in chickens were analyzed to see if these areas play a role in avian body weight regulation. In the first study, cycloheximide, glutamate, or saline was injected intracerebrally into 1-day-old chicks. In the second study, 3-day-old chicks received surgical ablation of the neocortex or kainic acid-induced lesions of the paleostriatum. Decreased body weight was noted in chicks that received injections of cycloheximide or glutamate, or kainic acid-induced lesions. The disruption in body weight in Experiment 1 might have been due to neurochemical pathology thought to occur in the paleostriatum. In the second experiment, lesions of the neostriatum or hyperstriatum, analogous to the neocortex in mammals, did not produce a difference in weight gain compared to controls. This preliminary work with kainic acid lesions in the chicken paleostriatum demonstrates a significant long-term decrease in body weight. As in mammals, the basal ganglia may have a role in body weight regulation.

Animals↗
PubMed1994

Recent advances in neural transplantation. Relevance to neurodegenerative disorders.

Anatomical and behavioral characterizations of neural transplants, whether within (allograft) or across (xenograft) species, have provided evidence that the transplant survives, integrates with the host tissue, and may lead to functional recovery. Several animal models of neurodegenerative disorders demonstrate the feasibility of using neural transplantation as an alternative treatment for these human diseases. While more elaborate basic animal studies are needed, clinical trials have begun. Neural transplantation is currently used as an experimental treatment for Parkinson's disease and several investigators have suggested using the same treatment procedure for other neurodegenerative disorders, such as Huntington's and Alzheimer's disease.

Alzheimer Disease↗
PubMed1994

Cell transplantation for central nervous system disorders.

Initially, the specific aim of transplantation studies was to investigate the regenerative capabilities of the mammalian nervous system. From this underlying impetus, a myriad of knowledge, spanning from molecular biology to neurobiology, has enhanced our understanding of regeneration and the applicability of fetal tissue transplantation in treating various neurodegenerative diseases. Current evidence suggests that transplantation of fetal neural tissue ameliorates the neurobiological and behavioral changes observed in animal models of central nervous system (CNS) disorders. In light of numerous basic science studies, clinical trials have begun to evaluate the potential of neural transplantation in treating human diseases. Indeed, modest progress has been reported in the treatment of Parkinson's disease. However, whereas fetal tissue transplantation has reached considerable success, it has also been observed to produce either no beneficial effects, magnify existing behavioral abnormalities, or even produce a unique constellation of deficits. Thus, while the prospects are promising, further investigations aimed at improving and refining existing transplantation paradigms are warranted before neural transplantation techniques can be of widespread value. This review article attempts to provide an overview of the neuroanatomical, neurochemical, and behavioral effects produced by transplanted fetal tissue in several animal models of CNS disorders. We have attempted to present both positive and adverse effects and to critically analyze the suitability of neural transplantation as a therapy for the various neurological disorders. In addition, alternative approaches, including the use of encapsulated neural tissue implants and genetically engineered cell lines along with their clinical potential, are discussed when appropriate.

Animals↗
PubMed1994

The biology of meningiomas.

Biochemical and molecular biological analyses of central nervous system tumors have progressed considerably in the last two decades. It may soon be possible to reclassify tumors according to biochemical or genetic criteria that relate directly to the tumor's individual biologic potential. Beyond informing a prognosis, these studies may also indicate strategies by which a tumor's biologic destiny can be altered or interrupted. With regard to meningiomas, this promise has not yet been fulfilled, although new agents such as mifepristone are achieving modest success. The greatest efforts thus far have been devoted to the study of sex steroid receptors. Historically, interest in this line of inquiry was enlivened by perceived parallels with hormone receptors identified in breast cancer tissue. Although investigative results have varied widely, a consensus has emerged that a majority of meningiomas harbor genuine PR and AR. These results are now confirmed by powerful molecular biologic techniques that interrogate for the presence of specific receptor mRNA. Whether these proteins represent functioning receptors remains highly controversial. Neither in vitro stimulation studies nor clinical experience has disclosed a consistent or convincing pattern of response to resolve this question. The possibility exists that the expression of these specific receptor proteins is but an epiphenomenon, the signature of the underlying neoplastic process, but functionally disconnected from its initiation or maintenance. The role that polypeptide growth factors and neurohumoral agents have in the biology of meningiomas is not yet clear but is an area of intense investigative effort. Attempts to elucidate the activity and interplay of these substances in in vitro cell culture assays have yielded inconsistent outcomes. These assays are extremely complex, and the results can be dramatically influenced by a host of recognized and unrecognized variables making interlaboratory comparisons difficult. A fundamental unknown is the fidelity of such cell culture assays in mirroring the in vivo biology of a given tumor. At least some of these difficulties are overcome in the direct molecular analysis of the tumor genome, which identifies specific genes and gene products in the primary specimen.(ABSTRACT TRUNCATED AT 400 WORDS)

Cell Division↗